
https://www.science.org/content/blog-post/nor-am-i-out-it
# ". . .Nor Am I Out of It" (January 2005)

## 1. SUMMARY

This opinion piece from early 2005 addresses the pharmaceutical industry's precarious situation, written by someone working within the field. The author expresses frustration with clinical pipeline limitations, industry leadership's inability to navigate political challenges, and an 85% clinical failure rate. The core argument is that the drug industry needs to focus on developing treatments for serious diseases like Alzheimer's, cancer, diabetes, and major depression rather than lifestyle enhancement products. The author warns against overhyping incremental advances, highlighting that exaggerated claims about "wonder drugs" or stem cell therapies ultimately damage credibility when they don't deliver on promises. The piece calls for long-term solutions rooted in better biological understanding and genuine medical need.

## 2. HISTORY

The pharmaceutical industry trajectory from 2005 onward reflects many of the author's concerns:

**Clinical Failure Rates**: The 85% failure rate mentioned persisted as a stubborn industry reality. Between 2006-2015, clinical trial success rates remained low across phases: approximately 90% for Phase I, 70% for Phase II, and 59% for Phase III. The industry continued struggling with targets that looked promising preclinically but failed in human trials due to incomplete biological understanding.

**Alzheimer's Drug Development**: This area proved particularly challenging, validating the author's concerns. Multiple major pharmaceutical companies invested billions in amyloid-targeting therapies, but between 2002-2012, 99.6% of Alzheimer's drug candidates failed in clinical trials. The few approved treatments provided only modest symptomatic benefits, not disease modification, and did little to move the needle on the global Alzheimer's burden.

**Stem Cell Hype and Reality**: The author's skepticism about stem cell hype proved prescient. While stem cell research advanced scientifically, commercial applications progressed much slower than predicted during the 2000s venture capital boom. Major challenges included manufacturing standardization, safety concerns, and reimbursement hurdles that prevented widespread clinical adoption of many promised therapies.

**Industry Consolidation**: The period saw significant mergers and acquisitions as companies struggled with patent cliffs and pipeline gaps - precisely the "short term we're stuck with what we have" problem the author anticipated.

## 3. PREDICTIONS

The author's implicit predictions and their outcomes:

• **Focus on genuine medical need over lifestyle drugs**: This prediction proved partially correct. While companies did continue pursuing lifestyle drugs, the most significant revenue successes came from oncology, immunology, and rare disease treatments where genuine medical need existed. Blockbusters like Keytruda (cancer immunotherapy, approved 2014), Humira for autoimmune conditions, and various rare disease therapies demonstrated that addressing serious unmet medical needs remained both profitable and reputation-enhancing for the industry.

• **Incremental advances shouldn't be hyped as breakthroughs**: The author's warning proved accurate. Multiple "breakthrough cancer drugs" indeed helped small percentages of their intended populations, leading to increased scrutiny of cost-effectiveness and shorter FDA approvals with mandatory post-marketing studies. The cancer immunotherapy revolution did eventually deliver meaningful advances, but the period between 2005-2015 was marked by many modest advances overhyped by both companies and media.

• **Stem cell therapy progress would take many years and consume significant venture capital**: This proved absolutely correct. The predicted "bonfires of venture capital" materialized, with many stem cell companies burning through hundreds of millions without reaching profitability or widespread clinical adoption. The timeline for meaningful stem cell therapies extended well beyond initial predictions.

## 4. INTEREST

Rating: **8/10**

The article demonstrates remarkable prescience about pharmaceutical industry challenges that remained relevant for the subsequent decade. Its clear-eyed assessment of hype cycles, realistic timelines, and focus on genuine medical need rather than commercial convenience makes it historically valuable for understanding both industry pressures and public perception dynamics.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20050103-nor-am-i-out-it.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_